News Archive

Context Therapeutics presented at the annual BIO Investor Forum on October 17-18, 2017. This event brings together blue chip institutional investors and emerging companies. 150 companies are selected to present, almost all of which are late stage private or public companies. 10 slots are reserved for company’s that have raised < $25M of capital and Context was selected as one of those 10 companies.

Context Therapeutics, a biotechnology company dedicated to creating new medicines for cancer, fibrosis, and neurodegenerative disease, today announced that the company has entered into agreements with three research partners.

The Coulter-Drexel Translational Research Partnership is pleased to announce the following six projects have been awarded funding for 2017-18. The mission of the Coulter-Drexel Translational Research Partnership is to partner with Drexel University faculty to develop products that will save, extend, and improve the lives of patients suffering from any disease or condition. Since inception of the program in 2005 nearly 50 projects have received a total of $7.6 million in support.

A team of Sidney Kimmel Cancer Center (SKCC) investigators from Thomas Jefferson University and Drexel University have recently published a new study in the journal Cancer Research that sheds light on a key mechanism of prostate cancer progression.

For 18-year-old Farheen Jahan, life took an ugly turn when she discovered a stiff growth in her breast. However, initial blood reports failed to detect anything serious. Later, in a health camp clinic set up in her locality in rural India she got herself scanned again with something called iBreastExam – a diagnostic tool designed to perform painless and radiation free breast scans, providing results instantly at the point of care. The scan detected abnormal tissue in her breast.

During the first year of Drexel’s Coulter Fellows Program in the School of Biomedical Engineering, Science and Health Systems, graduate students across the University worked together on medical and engineering research.

Jim currently serves as the CEO of PolyCore Therapeutics, a spin-out from Drexel University, focused on the development of a treatment for Parkinson’s Disease. Jim is also the CEO of LignaMed, LLC a spin-out from the University of Pennsylvania, focused on the development of an agent to improve outcomes in the treatment of chest Mr. Harris is the Co-founder and COO of FHK LLC, a company focused on acquisition and commercialization of specialty pharmaceutical products.

Tummy snugging maternity wear could soon be giving expecting parents peace of mind in addition to stylishly securing waistlines. Researchers at Drexel University are combining fashion design with wireless technology to produce a belly band that will be able to monitor uterine contractions and fetal heart rate in real time.

For medical devices, as with many medicines, the market for children is a small fraction of the adult market, and there are far fewer child-sized devices. But, of course, the need exists, even if proper devices may not.

A wristwatch that can check your blood pressure, a belly band for expecting mothers to monitor their baby’s vital signs and a way for doctors to sterilize their hands without getting them wet – these innovations are just a few of the ideas that will be on display as Drexel University and the Wallace H. Coulter Foundation provide a glimpse into the future of medical technology at the Innovation Technology & Talent Showcase on Oct. 31.

Physicians could soon have a new, noninvasive and radiation-free option when it comes to performing regular breast exams. A hand-held device, using technology developed at Drexel University, that can detect cancer by sensing the elasticity of breast tissue is moving into the final stages of testing and development with help from a Pennsylvania Department of Health grant.

Drexel University was awarded $10 million by the Wallace H. Coulter Foundation to endow the Coulter Translational Research Partnership program. The University matched the Coulter Foundation’s $10 million grant creating a $20 million endowment to bring life saving solutions to clinical practice by moving promising biomedical discoveries to commercialization.